Skip to content

2DG-abT therapy for malignant tumors

A clinical study on the safety of 2DG-abT cell therapy for malignant tumor.

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTc030210184
Enrollment
3
Registered
2021-07-05
Start date
2021-12-06
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant tumor

Interventions

Sponsors

Takimoto Rishu
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1)Be diagnosed with malignant tumor by imaging findings or pathological or cytological study. (2)Have an Eastern Cooperative Oncology Group performance-status score of 0 or 1. (3)Be 20 years of age or older. (4)Visit outpatient department on schedule. (5)Have an adequate function of liver, kidney, and bone marrow when the eligibility is confirmed. (6)Provide written consent to participate this study.

Exclusion criteria

Exclusion criteria: (1)Be apparent from the clinical manifestation of pulmonary fibrosis or interstitial pneumonia. (2)Have a history of a serious drug allergy. (3)Have a positive result of HIV antibody. (4)Have a serious cardiac disorder. (5)Have an active autoimmune disorder. (6)Have a concurrent cancer. (7)Have an infectious disorder that is difficult to control. (8)Be a female who is pregnant, lactating, or with a possibility of pregnancy. (9)A patient who is judged as inadequate for enrolment by doctors is excluded

Design outcomes

Primary

MeasureTime frame
Safety

Secondary

MeasureTime frame
Efficacy, Immunological response

Countries

Japan

Contacts

Public ContactEri Oguma

Koshikai, Non-profit Medical Corporation

citeg@j-immunother.com+81-3-5244-5751

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026